Speranza G, et al. – Experts planned to establish the safety and tolerability of PU–H71, as well as, to characterize its pharmacokinetic (PK) profile on a weekly administration schedule in human subjects with solid tumors refractory to standard treatments. In this study, with no dose limiting toxicities, PU–H71 was well tolerated at the doses administered during this study (10 to 470 mg/m2/day).